PMC:7417114 / 47621-48595 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T244","span":{"begin":385,"end":391},"obj":"Body_part"},{"id":"T245","span":{"begin":614,"end":620},"obj":"Body_part"},{"id":"T246","span":{"begin":621,"end":629},"obj":"Body_part"},{"id":"T247","span":{"begin":654,"end":662},"obj":"Body_part"},{"id":"T248","span":{"begin":821,"end":825},"obj":"Body_part"},{"id":"T249","span":{"begin":932,"end":936},"obj":"Body_part"}],"attributes":[{"id":"A244","pred":"fma_id","subj":"T244","obj":"http://purl.org/sig/ont/fma/fma9637"},{"id":"A245","pred":"fma_id","subj":"T245","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A246","pred":"fma_id","subj":"T246","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A247","pred":"fma_id","subj":"T247","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A248","pred":"fma_id","subj":"T248","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A249","pred":"fma_id","subj":"T249","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T68","span":{"begin":385,"end":391},"obj":"Body_part"},{"id":"T69","span":{"begin":821,"end":825},"obj":"Body_part"},{"id":"T70","span":{"begin":932,"end":936},"obj":"Body_part"}],"attributes":[{"id":"A68","pred":"uberon_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"A69","pred":"uberon_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A70","pred":"uberon_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T468","span":{"begin":726,"end":731},"obj":"Disease"},{"id":"T469","span":{"begin":808,"end":833},"obj":"Disease"},{"id":"T470","span":{"begin":821,"end":833},"obj":"Disease"},{"id":"T471","span":{"begin":852,"end":857},"obj":"Disease"},{"id":"T472","span":{"begin":919,"end":944},"obj":"Disease"},{"id":"T473","span":{"begin":932,"end":944},"obj":"Disease"}],"attributes":[{"id":"A468","pred":"mondo_id","subj":"T468","obj":"http://purl.obolibrary.org/obo/MONDO_0005233"},{"id":"A469","pred":"mondo_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A470","pred":"mondo_id","subj":"T470","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"},{"id":"A471","pred":"mondo_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/MONDO_0005233"},{"id":"A472","pred":"mondo_id","subj":"T472","obj":"http://purl.obolibrary.org/obo/MONDO_0015925"},{"id":"A473","pred":"mondo_id","subj":"T473","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T556","span":{"begin":48,"end":51},"obj":"http://purl.obolibrary.org/obo/UBERON_0001013"},{"id":"T557","span":{"begin":431,"end":434},"obj":"http://purl.obolibrary.org/obo/CLO_0054057"},{"id":"T558","span":{"begin":608,"end":613},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T559","span":{"begin":614,"end":620},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T560","span":{"begin":821,"end":825},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T561","span":{"begin":821,"end":825},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T562","span":{"begin":932,"end":936},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T563","span":{"begin":932,"end":936},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T414","span":{"begin":10,"end":18},"obj":"Chemical"},{"id":"T415","span":{"begin":337,"end":345},"obj":"Chemical"},{"id":"T416","span":{"begin":621,"end":629},"obj":"Chemical"},{"id":"T417","span":{"begin":654,"end":662},"obj":"Chemical"}],"attributes":[{"id":"A414","pred":"chebi_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/CHEBI_76003"},{"id":"A415","pred":"chebi_id","subj":"T415","obj":"http://purl.obolibrary.org/obo/CHEBI_75958"},{"id":"A416","pred":"chebi_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A417","pred":"chebi_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1492","span":{"begin":414,"end":418},"obj":"Gene"},{"id":"1561","span":{"begin":549,"end":557},"obj":"Species"},{"id":"1562","span":{"begin":608,"end":613},"obj":"Species"},{"id":"1563","span":{"begin":766,"end":774},"obj":"Species"},{"id":"1564","span":{"begin":889,"end":897},"obj":"Species"}],"attributes":[{"id":"A1492","pred":"tao:has_database_id","subj":"1492","obj":"Gene:5243"},{"id":"A1561","pred":"tao:has_database_id","subj":"1561","obj":"Tax:9606"},{"id":"A1562","pred":"tao:has_database_id","subj":"1562","obj":"Tax:9606"},{"id":"A1563","pred":"tao:has_database_id","subj":"1563","obj":"Tax:9606"},{"id":"A1564","pred":"tao:has_database_id","subj":"1564","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T129","span":{"begin":726,"end":731},"obj":"Phenotype"},{"id":"T130","span":{"begin":808,"end":833},"obj":"Phenotype"},{"id":"T131","span":{"begin":852,"end":857},"obj":"Phenotype"},{"id":"T132","span":{"begin":919,"end":944},"obj":"Phenotype"}],"attributes":[{"id":"A129","pred":"hp_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/HP_0030358"},{"id":"A130","pred":"hp_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/HP_0006530"},{"id":"A131","pred":"hp_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/HP_0030358"},{"id":"A132","pred":"hp_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/HP_0006530"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T163","span":{"begin":453,"end":463},"obj":"http://purl.obolibrary.org/obo/GO_0008152"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T384","span":{"begin":0,"end":19},"obj":"Sentence"},{"id":"T385","span":{"begin":20,"end":118},"obj":"Sentence"},{"id":"T386","span":{"begin":119,"end":346},"obj":"Sentence"},{"id":"T387","span":{"begin":347,"end":412},"obj":"Sentence"},{"id":"T388","span":{"begin":413,"end":587},"obj":"Sentence"},{"id":"T389","span":{"begin":588,"end":974},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}

{"project":"2_test","denotations":[{"id":"32778962-22200729-84130727","span":{"begin":407,"end":410},"obj":"22200729"},{"id":"32778962-28288939-84130728","span":{"begin":431,"end":434},"obj":"28288939"},{"id":"32778962-23816960-84130729","span":{"begin":964,"end":967},"obj":"23816960"},{"id":"32778962-24439929-84130730","span":{"begin":970,"end":973},"obj":"24439929"}],"text":"Afatinib (Gilotrif)\n(Boehringer Ingelheim) High fat meal decreases exposure by 50% (Cmax) and 39% (AUC (0 - infinity);\nfollowing oral dosing, Tmax=2 to 5 h; Cmax and AUC (0-infinity) values increased slightly more than dose proportional in range 20 to 50 mg; geometric mean relative bioavailability of 20 mg tablets=92% compared to oral solution;\nVd= 4500 L (suggests potentially high tissue distribution) (216);\n(P-gp substrate) (181) Enzyme-catalyzed metabolism plays insignificant role in vivo 40 mg orally once daily; 30 mg orally once daily in patients with severe renal impairment;\nin vitro binding to human plasma proteins is around 95%; binds to proteins both non-covalently (traditional binding) and covalently In an NSCLC clinical trial, among 230 treated patients, there were 3 cases of potential interstitial lung disease (1 %); in another NSCLC clinical trial, of 242 treated patients, 1 developed grade 4 interstitial lung disease however recovered (217) (218)"}